Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Saidel

Cornea and External Diseases Specialist Sonoma, CA Medical Doctor

NPI 1184780330 CMS profile 281269

181 Andrieux St Ste 100, Sonoma, CA 95476

Open in the dashboard

General payments

$51,411

244 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$69,393 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Michael Saidel of Sonoma, CA is reported in the CMS Open Payments database as having received $51,411 across 244 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $69,393 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Cornea and External Diseases Specialist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,007 29
2024 General $8,617 46
2023 General $938 40
2022 General $504 19
2021 General $3,207 29
2020 General $10,760 26
2019 General $26,378 55

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Saidel
  • Cornea and External Diseases Specialist median
  • Middle half of Cornea and External Diseases Specialist
  • National median

In program year 2025, general payments to Michael Saidel were reported at $1,007. Among 290 Cornea and External Diseases Specialist profiles paid that year, the median was $477 and the middle half received between $193 and $1,174.

Show as a table
Year Michael Saidel Cornea and External Diseases Specialist median Middle half National median
2019 $26,378 $276 $111–$734 $163
2020 $10,760 $146 $48–$330 $114
2021 $3,207 $254 $116–$566 $132
2022 $504 $251 $106–$729 $149
2023 $938 $344 $149–$759 $160
2024 $8,617 $366 $170–$927 $164
2025 $1,007 $477 $193–$1,174 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sun Pharmaceutical Industries Inc. $18,777 37 payments
  2. Glaukos Corporation $8,208 16 payments
  3. EyePoint Pharmaceuticals US, Inc. $8,091 17 payments
  4. Bausch & Lomb, a division of Bausch Health US, LLC $7,089 12 payments
  5. Integra LifeSciences Corporation $3,900 2 payments
  6. Kala Pharmaceuticals, Inc. $1,380 7 payments
  7. Alcon Vision LLC $1,042 37 payments
  8. AbbVie, Inc. $339 19 payments
  9. Bausch & Lomb Americas Inc. $302 17 payments
  10. Dompe US, Inc. $289 9 payments
  11. Other $1,994 71 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Honoraria $14,400 6 payments
  2. Consulting Fee $9,000 8 payments
  3. Long term medical supply or device loan $7,475 1 payment
  4. Food and Beverage $6,287 210 payments
  5. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $5,900 2 payments
  6. Travel and Lodging $4,275 10 payments
  7. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,900 2 payments
  8. Education $98 1 payment
  9. Gift $75 4 payments
Products named General payments · program years 2019–2025
  1. Cequa $18,731 33 payments
  2. DEXYCU $8,011 15 payments
  3. PROLENSA $4,657 4 payments
  4. BIODOPTIX $3,900 2 payments
  5. BIODFACTOR $3,900 2 payments
  6. BIODRESTORE $3,900 2 payments
  7. BIOFIX $3,900 2 payments
  8. LOTEMAX SM $2,328 6 payments
  9. EYSUVIS $1,348 5 payments
  10. OXERVATE $242 7 payments
  11. Other $5,134 200 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

1,067

Median for Ophthalmology: 891

Drug cost

$199,143

Median for Ophthalmology: $68,233

Branded share of claims

34.9%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Restasis Cyclosporine Brand 70 $54,924
Xiidra Lifitegrast Brand 42 $49,962
Cequa Cyclosporine Brand 25 $26,603
Lumigan Bimatoprost Brand 20 $12,921
Cyclosporine Generic 25 $10,431
Travoprost Generic 31 $7,880
Loteprednol Etabonate Generic 50 $7,163
Latanoprost Generic 308 $5,984
Rhopressa Netarsudil Mesylate Brand 13 $5,610
Prednisolone Acetate Generic 106 $4,956

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$424,915

Medicare's payments for the services billed

Medicare patients

1,360

Average age 76

Services billed

3,710

840 women, 520 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 47%
Diabetes 22%
Ischemic heart disease 21%
Depression 18%
Osteoporosis 18%
Atrial fibrillation 17%
Chronic kidney disease 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
IHEEZO
  • Harrow Eye, LLC $101
$101 — —
OXERVATE
  • Dompe US, Inc. $90
$90 — —
TYRVAYA
  • Oyster Point Pharma, Inc. $85
$85 — —
MIEBO
  • Bausch & Lomb Americas Inc. $68
$68 — —
Rocklatan
  • Alcon Vision LLC $63
$63 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

244 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cornea and External Diseases Specialist in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record